Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$39.34
$1.38(3.59%)
At close: 4:00 PM EDT
$39.34
$1.38(3.59%)
Day’s Range― - ―
52-Week Range$23.01 - $47.40
Previous CloseN/A
Volume19.90K
Average Volume (3M)84.11K
Market Cap
$227.07M
Enterprise Value$349.14M
Total Cash (Recent Filing)$20.45M
Total Debt (Recent Filing)$133.00K
Price to Earnings (P/E)20.0
Beta0.82
Next Earnings
Nov 10, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.37
Shares Outstanding8,287,085
10 Day Avg. Volume69,057
30 Day Avg. Volume84,112
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.48
Price to Sales (P/S)4.74
P/FCF Ratio41.56
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit6.03
Enterprise Value/Ebitda22.82
Forecast
1Y Price Target
$47.00Price Target Upside19.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.48
Revenue Forecast (FY)$83.60M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Operating LeverageStrong multi-year revenue growth combined with faster operating-income expansion indicates improving scale economics and sales productivity. If management sustains double-digit growth and operating leverage, Electromed can compound earnings while funding continued commercial investment without sacrificing profitability.
Conservative Balance Sheet And Positive Cash GenerationA debt-free balance sheet and positive operating cash flow provide meaningful financial flexibility for product development, sales expansion, acquisitions, or shareholder returns. Low leverage also reduces refinancing exposure and allows the company to pursue growth initiatives from a position of financial strength.
Expanding Payer Access And Sales ExecutionBroader payer coverage can improve the pool of eligible patients and reduce reimbursement friction, while faster digital order processing supports conversion and service efficiency. Together, these capabilities strengthen Electromed’s direct-to-patient model and can support durable volume growth.
Bears Say
Single-product ConcentrationReliance on SmartVest concentrates Electromed’s revenue, product development, and commercial execution around one therapy system. A product-specific clinical, reimbursement, competitive, or execution setback could therefore affect the company disproportionately until adjacent products or capabilities are developed.
Hospital Channel Weakness And Execution VolatilityThe hospital channel is currently a source of revenue volatility, with a sharp Q4 decline and inherently lengthy sales cycles. Although hospital account liaisons are being piloted, rebuilding this channel may require time and could make growth more dependent on the home-care business.
High U.S. Market ConcentrationHeavy dependence on the U.S. concentrates Electromed’s exposure to domestic payer policies, reimbursement practices, regulatory conditions, and patient demand. This limits geographic diversification and means changes in the U.S. healthcare environment could have an outsized effect on results.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $23.01 and its highest was $47.40 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $227.07M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on Aug 25, 2026. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.317 by $0.073.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.26.
How many shares outstanding does Electromed have?
Electromed has 8,287,085 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.39 in its last earnings report, beating expectations of $0.317. Following the earnings report the stock price went down -19.243%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.00 (19.47% Upside)
$47.00 (19.47% Upside)
Blogger Sentiment
Neutral
ELMD Sentiment 50%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.80%
12-Months-Change
Fundamentals
Return on Equity
23.38%
Trailing 12-Months
Asset Growth
23.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Company Deck
ELMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong financial and operational performance: record quarterly and annual revenue, expanding margins, significant operating leverage, robust cash flow, expanded payer coverage and sustained sales rep productivity. Key challenges include a sharp quarter-over-quarter decline in hospital revenue, single-product concentration, small but growing R&D investments, and reliance on the U.S. market. Overall, the positives—consistent double-digit growth, improving profitability, cash generation, and clear go-to-market initiatives—significantly outweigh the identifiable risks and execution items.View all ELMD earnings summariesELMD Stock 12 Month Forecast
Average Price Target
$47.00
▲(19.47% Upside)
Technical Analysis
Ownership Overview
7.18% Insiders
10.31% Mutual Funds
0.12% Other Institutional Investors
71.72% Public Companies and
Individual Investors